Velosbio
VelosBio is a biopharmaceutical company focused on transforming the lives of cancer patients by developing innovative therapies that target ROR1, including antibody-drug conjugates and bispecific antibodies for various hematologic malignancies and solid tumors.
Velosbio Overview
Velosbio Funding Rounds
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Merger/Acquisition | 12/18/2020 | ||||
| Series B | 7/2/2020 | ||||
| Series A | 5/8/2020 | ||||
| Early Stage VC | 7/10/2018 | ||||
| Seed Round | 2/8/2018 |
Velosbio Investors
| Investor | Investment Rounds | Lead Partner | Initial Investment | Other Notable Investments |
|---|---|---|---|---|
| Adage Capital Management | Series B | Series B (2020-07-02) | ||
| Janus Henderson Investors (NYS: JHG) | Series B | Series B (2020-07-02) | ||
| T. Rowe Price Group (NAS: TROW) | Series B | Series B (2020-07-02) | ||
| Venrock | Series B | Series B (2020-07-02) | ||
| Viking Global Investors | Series B | Series B (2020-07-02) | ||
| Wellington Management | Series B | Series B (2020-07-02) |
Velosbio 409a Valuations
| Date | Price per share | Est. Valuation | Filling |
|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Velosbio Filings
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
